Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer;Naczyniowo-śródbłonkowy czynnik wzrostu - VEGF i rozpuszczalny receptor - s VEGFR-1 w surowicy chorych na raka płuca

Pneumonologia i Alergologia Polska

Volumn 72, Issue 9-10, 2004, Pages 389-394

  Świdzińska, Ewa ^a   Ossolińska, Maria ^a   Naumnik, Wojciech ^a   Izycki, Tomasz ^a   Kucejko, Wojciech ^a   Chyczewska, Elzbieta ^a  

^a Klinika Chorob Pluc I Gruzlicy   (Poland)

Author keywords

Angiogenesis; Lung cancer; sVEGFR 1; VEGF

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ANGIOGENESIS; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG CANCER; MALE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 17344364157     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Belgore F. M. i wsp.: Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, FLT - 1, in haematological cancers: a comparison with breast cancer. Am. J. Hematol., 2001, 66, 1, 59-61.
2. Bergqvist M. i wsp.: bFGF and VEGF in serum from patients with non small cell lung cancer correlates to response of radiation treatment. Lung Cancer, 2000, 29, supp. 1, 172.
3. Choi J-H i wsp.: Vascular endothelial growth factor in the serum of patients with non - small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer, 2001, 33, 171-179.
4. Cox G.: Angiogenesis and non-small cell lung cancer. Lung Cancer, 2000, 27, 81-100.
5. Ferrara N.: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int., 1999, 56, 794-814.
6. Folkman J.: Clinical applications of research on angiogenesis. N. Engl. J. Med., 1995, 1995, 333, 1757-63.
7. Fontanini G. i wsp.: A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Brit J Cancer, 2002, 86, 4, 558-563.
8. Fontanini G. i wsp.: Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Brit J Cancer, 1999, 79, 2, 363-369.
9. Giatromanolaki A. i wsp.: Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res, 1998, 4, 3017-3024.
10. Goldman C. i wsp.: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibitis tumor growth, metastasis and mortality rate. Proc. Natl. Acad. Sci., 1998, 95, 8795-8800.
11. Hasumi Y.: Soluble FIT - 1 expression suppresses carcinomatous ascites im nude mice bearing ovarien cancer. Cancer Res., 2002, 1, 67, 7, 2019-23.
12. Imoto H. i wsp.: Vascular endothelial growth factor expression in non - small cell lung cancer: prognostic significance in squamous cell carcinoma. J. Thorac. Cardiovasc. Surg., 1998, 115, 1007-14.
13. Kido Y.: Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med. J. 2001, 48, 1, 43-7.
14. Kumar H. i wsp.: Soluble FLT - 1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res., 2002, 22, 3, 1877-80.
15. Matsuyama W. i wsp.: Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest, 2000, 118, 4, 945-51.
16. Mattern J., Koomägi R. and Volm M.: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Brit J Cancer, 1996, 73, 931-934.
17. Neufeld G.: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 1999, 13, 9-17.
18. Niklińska W. i wsp.: Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer, 2001, 34, 59-64.
19. O'Byrne K.J. i wsp.: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Brit J Cancer, 2000, 82, 8, 1427-1432.
20. Salven P. i wsp.: High pre - treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small - cell lung cancer. Int. J. Cancer, 1998, 79, 1144-1146.
21. Shibusa T., Shijubo N., Abe S.: Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res, 1998, 4, 1483-1487.
22. Suzuki M. i wsp.: Serum endostatin correlates with progression and prognosis of non - small cell lung cancer. Lung Cancer, 2002, 35, 29-34.
23. Takayama K. i wsp.: Suppresion of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 2000, 60, 2169-77.
24. Tamura M. i wsp.: Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol. Rep., 2001, 8, 5, 1097-102.
25. Wierzbowska A. i wsp.: Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw. 2003, 14, 149-53.